Home › Afraxis, Inc. And Servier Announce A Collaboration On ESP Platform For Drug Discovery In Central Nervous System Disorders
 

Keywords :   


Afraxis, Inc. And Servier Announce A Collaboration On ESP Platform For Drug Discovery In Central Nervous System Disorders

2013-05-01 06:34:08| drugdiscoveryonline News Articles

Afraxis, Inc. ("Afraxis") and Institut de Recherches Servier ("Servier") announced a non-exclusive platform collaboration using Afraxis' Enhanced Spine Platform (ESP) Technology for the discovery of drugs to treat central nervous system (CNS) disorders

Tags: system central drug platform

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
16.05'Time running out' plea over shipyard's future
16.05Eastern North Pacific Tropical Weather Outlook
16.05Atlantic Tropical Weather Outlook
16.05China's Nio unveils Tesla Model Y rival
16.05Could the US economy be doing too well?
16.05Eastern North Pacific Tropical Weather Outlook
16.05Atlantic Tropical Weather Outlook
16.05The man who turned his dead father into a chatbot
More »